Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis

References

• Sundar KM, Sires M. Sepsis induced immunosuppression: implications for secondary infections and complications. Indian J Crit Care Med. 2013;17(3):162–169.
   PubMedGoogle Scholar
• O’Brien JM, Naeem AA, Aberegg SK, et al. Sepsis. Am J Med. 2007;120:1012–1022.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.
   PubMed Web of Science ®Google Scholar
• Stevenson EK, Rubenstein AR, Radin GT, et al. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med. 2014;42(3):625–631.
   PubMed Web of Science ®Google Scholar
• Scott MJ, Godshall CJ, Cheadle WG. JAKs, STATs, cytokines, and sepsis. Clin Diagn Lab Immunol. 2002;9(6):1153–1159. .
   PubMedGoogle Scholar
• Lord JM, Midwinter MJ, Chen YF, et al. The systemic immune response to trauma: an overview of pathophysiology and treatment. Lancet. 2014;384(9952):1455–1465.
   PubMed Web of Science ®Google Scholar
• Skrupky LP, Kerby PW, Hotchkiss RS. Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology. 2011;115(6):1349–1362.
   PubMed Web of Science ®Google Scholar
• Ward PA. Immunosuppression in sepsis. JAMA. 2011;306(23):2618–2619.
   PubMed Web of Science ®Google Scholar
• Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–2605.
   PubMed Web of Science ®Google Scholar
• Treacher DF, Brown KA. The basic science of sepsis. Surgery. 2009;27(11):465–469.
   Google Scholar
• Rosenthal MD, Moore FA. Persistent inflammation, immunosuppression, and catabolism: evolution of multiple organ dysfunction. Surg Infect (Larchmt). 2016;17(2):167–172.
   PubMed Web of Science ®Google Scholar
• Sursal T, Stearns-Kurosawa DJ, Itagaki K, et al. Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile SIRS and quantify inflammatory tissue injury in nonhuman primates. Shock. 2013;39(1):55–62.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Opal SM, Marshall JC, et al. Sepsis definitions: time for change. Lancet. 2013;381(9868):774–775.
   PubMed Web of Science ®Google Scholar
• Sweeney TE, Shidham A, Wong HR, et al. A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set. Sci Transl Med. 2015;7(287):287ra71.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet. 2013;13:260–268.
   PubMed Web of Science ®Google Scholar
• Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: re-analysis of a prior Phase III trial. Crit Care Med. 2016;44(2):275–281.
   PubMed Web of Science ®Google Scholar
• Huang X, Venet F, Wang YL, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA. 2009;106(15):6303–6308.
   PubMed Web of Science ®Google Scholar
• Brahmamdam P, Inoue S, Unsinger J, et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88:233–240.
   PubMed Web of Science ®Google Scholar
• Chang KC, Burnham CA, Compton SM, et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care. 2013;17(3):R85.
   PubMed Web of Science ®Google Scholar
• Inoue S, Bo L, Bian J, et al. Dose dependent effect of anti-CTLA-4 on survival in sepsis. Shock. 2011;36(1):38–44.
   PubMed Web of Science ®Google Scholar
• Matsukawa A, Kaplan MH, Hogaboam CM, et al. Pivotal role of signal transducer and activator of transcription (STAT)4 and STAT6 in the innate immune response during sepsis. J Exp Med. 2001;193(6):679–688.
   PubMed Web of Science ®Google Scholar
• Gibot S, Massin F, Marcou M, et al. TREM-1 promotes survival during septic shock in mice. Eur J Immunol. 2007;37:456–466.
   PubMed Web of Science ®Google Scholar
• Gibot S, Kolopp-Sarda MN, Béné MC, et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med. 2004;200(11):1419–1426.
   PubMed Web of Science ®Google Scholar
• Wang F, Liu S, Wu S, et al. Blocking TREM-1 signaling prolongs survival of mice with Pseudomonas aeruginosa induced sepsis. Cell Immunol. 2012;272:251–258.
   PubMed Web of Science ®Google Scholar
• Angele MK, Catania RA, Ayala A, et al. Dehydroepiandrosterone: an inexpensive steroid hormone that decreases the mortality due to sepsis following trauma-induced hemorrhage. Arch Surg. 1998;133:1281–1288.
   PubMed Web of Science ®Google Scholar
• Schmitz D, Kobbe P, Wegner A, et al. Dehydroepiandrosterone during sepsis: does the timing of administration influence the effectiveness. J Surg Res. 2010;163:e73–e77.
   PubMed Web of Science ®Google Scholar
• Ben-Nathan D, Padgett DA, Loria RM. Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. J Med Microbiol. 1999;48:425–431.
   PubMed Web of Science ®Google Scholar
• Marcu AC, Kielar ND, Paccione KE, et al. Androstenetriol improves survival in a rodent model of traumatic shock. Resuscitation. 2006;71:379–386.
   PubMed Web of Science ®Google Scholar
• Marcu AC, Paccione KE, Barbee RW, et al. Androstenetriol immunomodulation improves survival in a severe trauma hemorrhage shock model. J Trauma. 2007;63:662–669.
   PubMedGoogle Scholar
• El-Menyar A, El-Hennawy H, Al-Thani H, et al. Traumatic injury among females: does gender matter? J Trauma Manag Outcomes. 2014;8:8.
   PubMedGoogle Scholar
• Choudry MA, Bland KI, Chaudry IH. Gender and susceptibility to sepsis following trauma. Endocr Metab Immune Disord Drug Targets. 2006;6(2):127–135.
   PubMedGoogle Scholar
• Yu HP, Chaudry IH. Sex differences in sepsis following trauma and injury. In: Klein SL, Roberts CW, editors. Sex and gender differences in infection and treatments for infectious diseases. Switzerland: Springer; 2015. p. 255–271.
   Google Scholar
• Jentzer JC, Murugan M. Use of corticosteroids in septic shock. SCCM Critical Connections. 2015 Apr 2. [cited 2016 Sep 15]. Available from: http://www.sccm.org/Communications/Critical-Connections/Archives/Pages/Use-of-Corticosteroids-in-Septic-Shock.aspx
   Google Scholar
• Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids - new mechanisms for old drugs. New Engl J Med. 2005;353(16):1711–1723.
   PubMed Web of Science ®Google Scholar
• Roquilly A, Mahe PJ, Seguin P, et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. JAMA. 2011;305(12):1201–1209.
   PubMed Web of Science ®Google Scholar
• Bulger EM, Cuschieri J. Steroids after severe injury: many unanswered questions. JAMA. 2011;305(12):1242–1244.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun J, Zheng J, et al. Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: a meta-analysis of randomized controlled trials. Anesth Analg. 2014;118(2):346–357.
   PubMed Web of Science ®Google Scholar
• Catania RA, Angele MK, Ayala A, et al. Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes. Cytokine. 1999;11:443–450.
   PubMed Web of Science ®Google Scholar
• Lichte P, Pfeifer R, Werner BE, et al. Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model. Eur J Med Res. 2014;19(1):27.
   PubMed Web of Science ®Google Scholar
• Szalay L, Shimizu T, Suzuki T, et al. Androstenediol administration after trauma-hemorrhage attenuates inflammatory response, reduces organ damage, and improves survival following sepsis. Am J Physiol Gastrointest Liver Physiol. 2006;291:G260–G266.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Shimizu T, Szalay L, et al. Androstenediol ameliorates alterations in immune cells cytokine production capacity in a two-hit model of trauma-hemorrhage and sepsis. Cytokine. 2006;34:76–84.
   PubMed Web of Science ®Google Scholar
• Loria RM, Conrad DH, Carter H, et al. Androstenetriol and androstenediol protection against lethal radiation and restoration of immunity after radiation injury. Ann NY Acad Sci. 2000;917:860–867.
   PubMed Web of Science ®Google Scholar
• Loria RM. Antiglucocorticoid function of androstenetriol. Psychoneuroendrocrinology. 1997;22:S103–S108.
   PubMed Web of Science ®Google Scholar
• Su L, Liu D, Chai W, et al. Role of sTREM-1 in predicting mortality of infection: a systematic review and meta-analysis. BMJ Open. 2016;6(5):e010314.
   PubMed Web of Science ®Google Scholar
• Lin YT, Tseng KY, Yeh YC, et al. TREM-1 promotes survival during Klebsiella pneumoniae liver abscess in mice. Infect Immun. 2014;82(3):1335–1342.
   PubMed Web of Science ®Google Scholar
• Lagler H, Sharif O, Haslinger I, et al. TREM-1 activation alters the dynamics of pulmonary IRAK-M expression in vivo and improves host defense during Pneumococcal pneumonia. J Immunol. 2009;183:2027–2036.
   PubMed Web of Science ®Google Scholar
• Bouchon A, Facchetti F, Welgand MA, et al. TREM-1 amplifies inflammation and is crucial mediator of septic shock. Nature. 2001;410:1103–1107.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang F, Fan X, et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care. 2012;16:R229–R242.
   PubMed Web of Science ®Google Scholar
• Oku R, Oda S, Nakada TA, et al. Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine. 2012;61:112–117.
   PubMed Web of Science ®Google Scholar
• Samraj RS, Zingarelli B, Wong HR. Role of biomarkers in sepsis care. Shock. 2013;40(5):358–365.
   PubMed Web of Science ®Google Scholar
• Tranca S, Oever JT, Ciuce C, et al. sTREM-1, sIL-2Ra, and IL-6, but not sCD163, might predict sepsis in polytrauma patients: a prospective cohort study. Eur J Trauma Emerg Surg. 2017 Jun;43(3):363–370. doi: 10.1007/s00068-016-0678-1. Epub 2016 May 12.
   PubMed Web of Science ®Google Scholar
• Gibot S, Le Renard PE, Bollaert PE, et al. Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med. 2005;31:594–597.
   PubMed Web of Science ®Google Scholar
• Brenner T, Uhle F, Fleming T, et al. Soluble TREM-1 as a diagnostic and prognostic biomarker in patients with septic shock: an observational clinical study. Biomarkers. 2016;6:1–7.
   Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T-lymphocyte associated antigen-4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712–4717.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Mouktaroudi M, Tsaganos T, et al. Evidence for the participation of soluble triggering receptor expressed on myeloid cells-1 in the systemic inflammatory response syndrome after multiple trauma. J Trauma. 2008;65(6):1385–1390.
   PubMedGoogle Scholar
• Pontrelli G, De Crescenzo F, Buzzetti R, et al. Diagnostic value of soluble triggering receptor expressed on myeloid cells in paediatric sepsis: a systematic review. Ital J Pediatr. 2016;42:44–54.
   PubMed Web of Science ®Google Scholar
• Gibot S, Massin F, Le Renard P, et al. Surface and soluble triggering receptor expressed on myeloid cells-1: expression patterns in murine sepsis. Crit Care Med. 2005;33(8):1787–1793.
   PubMed Web of Science ®Google Scholar
• Fortin CF, Lesur O, Fulop T Jr. Effects or TREM-1 activation in human neutrophils: activation of signaling pathways, recruitment into lipid rafts and association with TLR4. Int Immun. 2006;19(1):41–50.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–824.
   PubMed Web of Science ®Google Scholar
• Brown KE, Freeman GJ, Wherry EJ, et al. Role of Pd-1 in regulating acute infections. Curr Opin Immunol. 2010;25:477–483.
   Google Scholar
• Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci. USA. 2003;100(9):5336–5341.
   PubMed Web of Science ®Google Scholar
• Kirchberger S, Majdic O, Steinberger P, et al. Human rhinovirus inhibits the accessory function of dendritic cells by inducing sialoadhesion and B7-H1 expression. J Immunol. 2005;175(2):1145–1152.
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–687.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou Y, Lou J, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care. 2010;14(6):R220.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Lou J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011;15(1):R70.
   PubMed Web of Science ®Google Scholar
• Guignant C, Lepape A, Huang X, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunction in septic shock patients. Crit Care. 2011;15(2):R99.
   PubMed Web of Science ®Google Scholar
• Chang K, Svabek C, Vazquez-Guillamet C, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014;18(1):R3.
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Hamid O, Urba WJ. Targeting cytotoxic t-lymphocyte antigen-4 (CTLA-4). A novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110(12):2614–2627.
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-Cell activation by distinct mechanism. Mol Cell Bio. 2005;25(21):9543–9553.
   PubMed Web of Science ®Google Scholar
• Tarhini A. Immune-Mediated adverse events associated with Ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica. 2013;2013:857519.
   PubMedGoogle Scholar
• Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase 1 trial with the anti-cytotoxic T-lymphocyte associated antigen-4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968–8977.
   PubMed Web of Science ®Google Scholar
• Gomez-Navarro J, Sharma A, Bozon V, et al. Dose and schedule selection for the anti-CTLA4 monoclonal antibody CP-675,206 in patients with metastatic melanoma. J Clin Oncol. 2006;24(18s):8032.
   Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus Ipilimumab in advanced melanoma. New Engl J Med. 2013;369(2):122–133.
   PubMed Web of Science ®Google Scholar
• Matusukawa A. STAT proteins in innate immunity during sepsis: lessons from gene knockout mice. Acta Medica Okayama. 2007;61(5):239–245.
   PubMed Web of Science ®Google Scholar
• Zolfaghari PS, Pinto BB, Dyson A, et al. The metabolic phenotype of rodent sepsis: cause for concern? Intensive Care Med Exp. 2013;1:6.
   Google Scholar
• Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2013;110(9):3507–3512.
   PubMed Web of Science ®Google Scholar
• Fink MP. Animal models of sepsis. Virulence. 2014;5(1):143–153.
   PubMed Web of Science ®Google Scholar
• Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195–203.
   PubMed Web of Science ®Google Scholar
• Dejager L, Pinheiro I, Dejonckheere E, et al. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol. 2011;19(4):198–208.
   PubMed Web of Science ®Google Scholar
• Unsinger J, McDonough JS, Shultz LD, et al. Sepsis-induced human lymphocyte apoptosis and cytokine production in “humanized” mice. J Leukoc Biol. 2009;86:219–227.
   PubMed Web of Science ®Google Scholar